Advanced Biomed (ADVB) vs Fulgent Genetics (FLGT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fulgent Genetics (FLGT) has outperformed Advanced Biomed (ADVB) over the past year, losing 8.8% versus a loss of 34.9%. Fulgent Genetics is the larger company by market cap ($572.9 million vs $10.1 million), about 56.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADVB | FLGT |
|---|---|---|
| Share price | $6.12 | $20.82 |
| Market cap | $10.11M | $572.87M |
| 1-day change | -2.86% | +1.22% |
| YTD return | +4.79% | -20.75% |
| 1-year return | -34.89% | -8.80% |
| 5-year return | — | -73.31% |
| P/E ratio (TTM) | 1.26 | — |
| EPS (TTM) | $4.85 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.23 | $31.04 |
| 52-week low | $3.61 | $13.46 |
| Distance from 52-week high | -74.74% | -32.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | -8.74% |
| Average volume | 1.75M | 298.26K |
| Shares outstanding | 1.65M | 27.52M |
| Employees | 31 | 1,315 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Fulgent Genetics is about 56.7 times larger than Advanced Biomed by market value ($572.87M vs $10.11M).
- FLGT has outperformed ADVB by 26.1 percentage points over the past year.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Healthcare · Diagnostics & Research · 31 employees
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Healthcare · Diagnostics & Research · 1,315 employees
ADVB vs FLGT FAQ
Which is bigger, Advanced Biomed or Fulgent Genetics?
Fulgent Genetics (FLGT) is larger, with a market capitalization of $572.87M compared with $10.11M for Advanced Biomed (ADVB).
Which stock has performed better over the past year, ADVB or FLGT?
FLGT returned -8.80% over the past 12 months, compared with -34.89% for ADVB (price return, excluding dividends). Past performance does not predict future results.
Are Advanced Biomed and Fulgent Genetics in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.